Burtea Carmen, Laurent Sophie, Vander Elst Luce, Muller Robert N
Department of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons-Hainaut, 24, Avenue du Champ de Mars, 7000, Mons, Belgium.
Handb Exp Pharmacol. 2008(185 Pt 1):135-65. doi: 10.1007/978-3-540-72718-7_7.
Even though the intrinsic magnetic resonance imaging (MRI) contrast is much more flexible than in other clinical imaging techniques, the diagnosis of several pathologies requires the involvement of contrast agents (CAs) that can enhance the difference between normal and diseased tissues by modifying their intrinsic parameters. MR CAs are indirect agents because they do not become visible by themselves as opposed to other imaging modalities. The signal enhancement produced by MRI CAs (i.e., the efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) relaxivity (expressed in s(-1) mmol(-1) 1), which is defined as the increase of the nuclear relaxation rate (the reciprocal of the relaxation time) of water protons produced by 1 mmol per liter of CA. Paramagnetic CAs (most of them complexes of gadolinium) are frequently used in clinics as extracellular, hepatobiliary or blood pool agents. Low molecular weight paramagnetic CAs have similar effects on R1 and R2, but the predominant effect at low doses is that of T1 shortening (and R1 enhancement). Thus, organs taking up such agents will become bright in a T1-weighted MRI sequence; these CAs are thus called positive contrast media. The CAs known as negative agents influence signal intensity mainly by shortening T2* and T2, which produces the darkening of the contrast-enhanced tissue. These CAs are generally composed of superparamagnetic nanoparticles, consisting of iron oxides (magnetite, Fe3O4, maghemite, gammaFe2O3, or other ferrites). Iron oxide nanoparticles are taken up by the monocyte-macrophage system, which explains their potential application as MRI markers of inflammatory and degenerative disorders. Most of the contemporary MRI CAs approved for clinical applications are non-specific for a particular pathology and report exclusively on the anatomy and the physiological status of various organs. A new generation of MRI CAs is progressively emerging in the current context of molecular imaging, agents that are designed to detect with a high specificity the cellular and molecular hallmarks of various pathologies.
尽管磁共振成像(MRI)的固有对比度比其他临床成像技术更加灵活,但对于几种病症的诊断仍需要使用造影剂(CAs),这些造影剂可通过改变其固有参数来增强正常组织与病变组织之间的差异。MR造影剂是间接造影剂,因为与其他成像方式不同,它们本身不会显影。MRI造影剂产生的信号增强(即造影剂的效率)取决于其纵向(r1)和横向(r2)弛豫率(以s(-1) mmol(-1) 1表示),其定义为每升1 mmol造影剂产生的水质子核弛豫率(弛豫时间的倒数)的增加。顺磁性造影剂(其中大多数是钆的络合物)在临床上经常用作细胞外、肝胆或血池造影剂。低分子量顺磁性造影剂对R1和R2有相似的作用,但在低剂量时的主要作用是T1缩短(以及R1增强)。因此,摄取此类造影剂的器官在T1加权MRI序列中会变亮;这些造影剂因此被称为阳性造影剂。被称为阴性造影剂的造影剂主要通过缩短T2*和T2来影响信号强度,这会导致造影增强组织变暗。这些造影剂通常由超顺磁性纳米颗粒组成,由氧化铁(磁铁矿,Fe3O4,磁赤铁矿,γFe2O3或其他铁氧体)组成。氧化铁纳米颗粒被单核细胞-巨噬细胞系统摄取,这解释了它们作为炎症和退行性疾病的MRI标记物的潜在应用。目前批准用于临床的大多数当代MRI造影剂对特定病症都不具有特异性,仅报告各种器官的解剖结构和生理状态。在当前分子成像的背景下,新一代MRI造影剂正在逐渐出现,这些造影剂旨在以高特异性检测各种病症的细胞和分子特征。